09:06 AM EST, 01/10/2025 (MT Newswires) -- Revvity ( RVTY ) said Friday the Food and Drug Administration has cleared EUROIMMUN's automated chemiluminescence-based immunoassay test, which is used for measuring free testosterone levels.

The test is the first FDA-cleared assay for direct measurement of free testosterone in human serum or plasma, the company said.

Revvity ( RVTY ) said that the test delivers results in 48 minutes with a output of nearly 60 tests per hour.

The assay is designed to diagnose androgen disorders, including hypogonadism, impotence, and polycystic ovarian syndrome, Revvity ( RVTY ) said.